Belite Bio, Inc (BLTE)
| Previous close | 38.38 |
| Open | 38.50 |
| Bid | 28.80 x 200 |
| Ask | 40.17 x 100 |
| Day's range | 38.46 - 40.22 |
| 52-week range | 11.00 - 48.60 |
| Volume | |
| Avg. volume | 48,704 |
| Market cap | 1.183B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.19 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 56.50 |
GlobeNewswireBelite Bio Announces $25 Million Registered Direct Offering
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has entered into a securities purchase agreement with an institutional investor, for the purchase and sale of up to an aggregate of 651,380 American Depositary Shares of the Company (
ZacksDoes Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect?
The consensus price target hints at a 41.1% upside potential for Belite Bio (BLTE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- GlobeNewswire
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD)Data from a 24-month Phase 2 trial in adolescent STGD1 subjects showed a sustained lower atrophic lesion growth in Tinlarebant-treated subjects compared to ProgStar participants possessing similar baseline characteristics (aged ≤18 years) (p<0.001)In the Phase 2 trial,
